iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments and Fair Value Measurement (Narrative) (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed assets impairments				$ 3,100,000	$ 17,600,000	$ 17,900,000
Proceeds from Sale of Buildings		$ 17,250,000
Fixed assets held for sale	$ 13,024,000		$ 16,124,000	13,024,000		16,124,000
Discontinued Operations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed assets impairments	3,100,000					17,900,000
Buildings and improvements [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair values	12,964,000			12,964,000
Fixed assets impairments			300,000
Fixed assets held for sale			$ 16,100,000			$ 16,100,000
Fair Value, Nonrecurring [Member] \| Buildings and improvements [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair values	16,350,000			16,350,000
Fixed assets impairments				6,300,000
Fair Value, Nonrecurring [Member] \| Machinery and equipment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair values	$ 2,100,000			2,100,000
Fixed assets impairments				$ 11,300,000